Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHIDUE)

Drug Name
Phenelzine Drug Info
Synonyms
Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Skin imperfections EK71 Patented [2]
Therapeutic Class
Antidepressants
Cross-matching ID
PubChem CID
3675
ChEBI ID
CHEBI:8060
CAS Number
CAS 51-71-8
TTD Drug ID
DMHIDUE
INTEDE Drug ID
DR1272
ACDINA Drug ID
D00524

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Monoamine oxidase (MAO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [2]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [2]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [2]
Methylene blue DMJAPE7 Acquired methemoglobinemia 3A93 Approved [9]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [2]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [2]
Ergoloid mesylate DMORPBA Alzheimer disease 8A20 Approved [10]
Cyclopropylamine derivative 11 DMMJ0YN N. A. N. A. Patented [11]
PMID27019002-Compound-20a DMRX748 N. A. N. A. Patented [11]
Cyclopropylamine derivative 9 DMX7YAL N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [12]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [13]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [14]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [15]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [16]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [17]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [18]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [19]
Budipine DMODHQI Migraine 8A80 Approved [20]
Safinamide DM0YWJC Parkinson disease 8A00.0 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [22]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [23]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [24]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [25]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [28]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [29]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [23]
Verapamil DMA7PEW Angina pectoris BA40 Approved [30]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [50]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [51]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [52]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [53]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [54]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [54]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [55]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [56]
Capsaicin DMGMF6V Back pain ME84.Z Approved [57]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [58]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [31]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [32]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [35]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [36]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [37]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [38]
Verapamil DMA7PEW Angina pectoris BA40 Approved [39]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [40]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [41]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [42]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [43]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [44]
Verapamil DMA7PEW Angina pectoris BA40 Approved [45]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [48]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [59]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [60]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [59]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [60]
Sulfinpyrazone DMEV954 Gout FA25 Approved [61]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [59]
Zafirlukast DMHNQOG Asthma CA23 Approved [59]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [59]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [62]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [64]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [65]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [66]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [67]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [68]
Clopidogrel DMOL54H Acute coronary syndrome BA41 Approved [69]
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [70]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [71]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [72]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [74]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [6]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [75]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [76]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [77]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [78]
Ethacrynic acid DM60QMR Edema MG29 Approved [79]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [80]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [81]
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [82]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [83]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [84]
Galantamine DMEO794 Alzheimer disease 8A20 Approved [85]
Rivastigmine DMG629M Alzheimer disease 8A20 Approved [86]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [87]
Succinylcholine DM2ET1M Plasma cell myeloma 2A83.1 Approved [88]
Ethopropazine DM0N3L7 Parkinson disease 8A00.0 Approved [84]
Dimenhydrinate DM264B3 Meniere disease AB31.0 Approved [89]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [90]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [91]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [92]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [93]
Estrone DM5T6US Acne vulgaris ED80 Approved [94]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [95]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [96]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [97]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [98]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [99]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [2]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [4]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [4]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Gene/Protein Processing [5]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [6]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [6]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [7]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Gene/Protein Processing [8]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7266).
2 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
4 An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
5 Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J. 1969 Aug 30;3(5669):510-2. doi: 10.1136/bmj.3.5669.510.
6 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
7 Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
8 Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
9 Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
12 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
13 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
15 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
16 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
17 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
18 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
20 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
21 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
22 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
23 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
24 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
25 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
26 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
27 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
28 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
29 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
30 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
31 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
32 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
33 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
34 Drug Interactions Flockhart Table
35 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
36 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
37 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
38 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
39 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
40 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
41 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
42 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
43 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
44 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
45 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
46 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
47 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
48 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
49 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
50 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
51 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
52 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
53 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
54 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
55 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
56 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
57 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
58 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
59 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
60 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
61 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
62 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
63 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
64 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
65 Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
66 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
67 Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
68 Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
69 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
70 Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
71 Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
72 Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
73 Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
74 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
75 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
76 Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
77 Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
78 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
79 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
80 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
81 The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
82 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
83 Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
84 Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
85 Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
86 Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
87 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
88 Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
89 Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
90 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
91 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
92 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
93 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
94 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
95 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
96 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
97 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
98 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
99 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.